\
&
Contact us
\
&
Contact us
Published on | 9 minutes ago
Programmes Agro-Food, EnvironmentThe new Bioeconomy Strategy outlines a path for building a clean and competitive economy by tapping into renewable resources from land and sea. This strategy not only aims to create jobs but also intends to position Europe as a leader in the transition to clean industries. The bioeconomy currently accounts for a value of up to €2.7 trillion in 2023 and supports approximately 17.1 million jobs in the EU.
The strategy outlines the need to scale up innovation and develop lead markets for bio-based materials by encouraging investments in sectors including agriculture, biomanufacturing, and biotechnology. The European Commission will work to create a coherent and simplified regulatory framework that rewards circular and sustainable business models, while safeguarding EU safety standards. Faster, clearer and simpler approvals for innovative solutions will support companies to develop and grow in Europe, especially for SMEs.
Interested parties are encouraged to explore the implications of the Bioeconomy Strategy. More information can be found here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
